MB Therapeutics

Executive Summary

MB Therapeutics is a French biotechnology company pioneering pharmaceutical 3D printing to enable personalized medicine. Founded in 2018, the company offers an integrated platform comprising printers, software, and material development services, allowing on-demand production of customized medications tailored to individual patient needs. This technology addresses critical limitations of mass-produced drugs by enabling precise dosage, flexible form, and drug combination, thereby improving therapeutic outcomes and adherence. Targeting both retail pharmacies and pharmaceutical manufacturers, MB Therapeutics aims to transform the drug supply chain from a one-size-fits-all model to personalized, point-of-care manufacturing. The company has reached Phase 2 development, indicating its technology has moved beyond proof-of-concept to validated applications. While financial details remain undisclosed as a private entity, MB Therapeutics is positioned at the intersection of digital health and advanced manufacturing. Its platform has the potential to disrupt traditional drug formulation, particularly for patient populations requiring dose personalization, such as pediatrics, geriatrics, and those with metabolic variations. With regulatory frameworks for 3D-printed drugs evolving, the company is well-placed to capitalize on the growing demand for personalized healthcare. Near-term catalysts include securing strategic partnerships with pharmacy chains and advancing regulatory clearances for its printer-pharmacy workflow integration.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major European pharmacy chain for pilot deployment of 3D printing stations45% success
• Q4 2026Publication of clinical validation study demonstrating efficacy of 3D-printed personalized doses50% success
• Q3 2026Launch of next-generation 3D printer model with enhanced speed and formulation flexibility35% success